Eckert & Ziegler has executed with the Canadian biotech company Alpha-9 Theranostics Inc.,  a clinical supply agreement for Eckert & Ziegler's medical radioisotope Lutetium-177 (non-carrier-added 177Lu). The isotope will be used for the clinical development of Alpha-9's investigational drugs.

Eckert & Ziegler has developed a unique, stable and reliable method to produce a highly pure form of Lu-177 n.c.a. which will be used by Alpha-9 for the clinical trials of its therapeutic candidates for solid and hematologic malignancies.

To read more please visit:

 Eckert & Ziegler to Supply Canadian Alpha-9 Theranostics with Lutetium-177 for Clinical Trials

Source: ITM